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Summary
Background Melioidosis, an infectious disease caused by the Gram-negative bacillus Burkholderia pseudomallei, is 
diﬃ  cult to cure. Antimicrobial treatment comprises intravenous drugs for at least 10 days, followed by oral drugs for 
at least 12 weeks. The standard oral regimen based on trial evidence is trimethoprim-sulfamethoxaxole (TMP-SMX) 
plus doxycycline. This regimen is used in Thailand but is associated with side-eﬀ ects and poor adherence by patients, 
and TMP-SMX alone is recommended in Australia. We compared the eﬃ  cacy and side-eﬀ ects of TMP-SMX with 
TMP-SMX plus doxycycline for the oral phase of melioidosis treatment.
Methods For this multi-centre, double-blind, non-inferiority, randomised placebo-controlled trial, we enrolled patients 
(aged ≥15 years) from ﬁ ve centres in northeast Thailand with culture-conﬁ rmed melioidosis who had received a 
course of parenteral antimicrobial drugs. Using a computer-generated sequence, we randomly assigned patients to 
receive TMP-SMX plus placebo or TMP-SMX plus doxycycline for 20 weeks (1:1; block size of ten, stratiﬁ ed by study 
site). We followed patients up every 4 months for 1 year and annually thereafter to the end of the study. The primary 
endpoint was culture-conﬁ rmed recurrent melioidosis, and the non-inferiority margin was a hazard ratio (HR) of 1·7. 
This study is registered with www.controlled-trials.com, number ISRCTN86140460.
Findings We enrolled and randomly assigned 626 patients: 311 to TMP-SMX plus placebo and 315 to TMP-SMX plus 
doxycycline. 16 patients (5%) in the TMP-SMX plus placebo group and 21 patients (7%) in the TMP-SMX plus 
doxycycline group developed culture-conﬁ rmed recurrent melioidosis (HR 0·81; 95% CI 0·42–1·55). The criterion 
for non-inferiority was met (p=0.01). Adverse drug reactions were less common in the TMP-SMX plus placebo group 
than in the TMP-SMX plus doxycycline group (122 [39%] vs 167 [53%]).
Interpretation Our ﬁ ndings suggest that TMP-SMX is not inferior to TMP-SMX plus doxycycline for the oral phase of 
melioidosis treatment, and is preferable on the basis of safety and tolerance by patients.
Funding Thailand Research Fund, the Melioidosis Research Center, the Center of Excellence in Speciﬁ c Health 
Problems in Greater Mekong Sub-region cluster, and the Wellcome Trust.
Introduction
Melioidosis is a serious infection caused by the Gram-
negative bacillus Burkholderia pseudomallei, found in soil 
and water.1 The reported incidence of human melioidosis 
is highest in northeast Thailand (crude case fatality rate 
43%) and northern Australia (14%).2,3 Melioidosis also 
aﬀ ects travellers to melioidosis-endemic regions of the 
world,4 which includes much of Asia, regions of South 
America, various Paciﬁ c and Indian Ocean islands, and 
some countries in Africa including Nigeria, Gambia, 
Kenya, and Uganda.1 First-line initial antimicrobial 
treatment is parenteral ceftazidime or a carbapenem 
drug (either meropenem or imipenem) for at least 
10 days.5 Patients are then switched to oral antimicrobials 
for at least 12 weeks. This extended period of treatment 
compared with most other bacterial infections is needed 
to achieve cure and prevent recurrent infection,5 which 
has been reported to occur in 16% of cases within 10 years 
of the primary infection and has a case fatality rate of 
24% in Thailand.6
The recommended oral antimicrobial regimen for 
melioidosis in Thailand is trimethoprim-sulfa meth-
oxazole (TMP-SMX) plus doxy cycline. This recom-
mendation is based on ﬁ ndings that this regimen is as 
eﬀ ective as, and better tolerated than, the previously 
recommended regimen of TMP-SMX plus doxycycline 
and chloramphenicol.7 However, a quarter of patients 
with melioidosis given TMP-SMX plus doxycycline 
develop an adverse drug reaction.7 Such adverse reactions 
often results in a switch to second-line treatment (usually 
amoxicillin-clavulanic acid), which is strongly associated 
with an increased risk of relapse.6 Findings from a 
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descriptive 10 year cohort study done in Australia 
reported recurrent infection in less than 2% of patients 
(one of 60 patients) who had oral treatment with TMP-
SMX alone;8 TMP-SMX has since become the standard 
regimen in Australia3 and is occasionally used in 
Thailand.9 We proposed that TMP-SMX alone was an 
adequate treatment for melioidosis, and did a clinical 
trial to compare the eﬃ  cacy and safety of TMP-SMX 
versus TMP-SMX plus doxycycline for the oral treatment 
phase of melioidosis.
Methods
Study design and participants
We did this multicentre, double-blind, non-inferiority, 
randomised placebo-controlled trial in ﬁ ve hospitals in 
northeast Thailand: Sappasithiprasong Hospital (Ubon 
Ratchathani), Srinagarind Hospital (Khon Kaen), Udon 
Thani Hospital (Udon Thani), Mahasarakam Hospital 
(Mahasarakam), and Khon Kaen Hospital (Khon Kaen). 
We enrolled adult patients (aged ≥15 years) with culture-
conﬁ rmed melioidosis who had been satisfactorily 
treated with parenteral antimicrobials, or who had mild 
localised disease that was not considered to need 
intravenous antimicrobial treatment by the attending 
physicians. We deﬁ ned satisfactory clinical improvement 
from parenteral treatment as cessation of fever for at 
least 48 h and the ability to take oral drugs. We excluded 
patients if they were infected by B pseudomallei that was 
resistant to TMP-SMX or doxycycline, if their melioidosis 
infection was recurrent (deﬁ ned as having a previous 
episode of culture-conﬁ rmed melioidosis within the past 
2 years), or if they had a contraindication to either TMP-
SMX or doxycycline (pregnancy, lactation, glomerular 
ﬁ ltration rate <15 mL/min estimated by the Cockcroft-
Gault equation, aspartate aminotransferase more than 
ﬁ ve times the upper limit of normal, alanine 
aminotransferase more than ﬁ ve times the upper limit of 
normal, known glucose-6-phosphase dehydrogenase 
deﬁ ciency, or history of hypersensitivity to TMP-SMX, 
doxycycline, or both). Resistance to doxycycline was 
determined by disc diﬀ usion as an inhibition zone 
diameter ≤12 mm, which was modiﬁ ed from the Clinical 
and Laboratory Standards Institute (CLSI) breakpoint 
recommended for Enterobacteriaceae.10,11 Resistance to 
TMP-SMX was determined by Etest (AB Biodisk, Solna, 
Sweden) as a minimum inhibitory concentration of 
4/76 mg/L or higher, which was modiﬁ ed from the CLSI 
breakpoint for B pseudomallei determined by broth 
dilution method.11,12
The trial was done in accordance with the principles of 
good clinical practice, and the ethical principles in the 
Declaration of Helsinki. The study protocol was approved 
by the local ethical committees and the institutional 
review boards of all participating hospitals. The study 
was reviewed by an independent data safety and 
monitoring board. All patients gave signed or 
ﬁ ngerprinted informed consent before randomisation. 
This trial is registered with www.controlled-trials.com, 
number IRSCTN86140460.
Randomisation and masking
We randomly allocated patients in a 1:1 ratio to receive TMP-
SMX with either placebo doxycycline (hereafter referred to 
as placebo) or doxycycline, which were identical in 
appearance. Randomisation and masking was done at the 
coordinating centre at the Mahidol-Oxford Tropical 
Medicine Research Unit (Bangkok, Thailand). The 
allocation sequence was computer generated with a block 
size of ten and was stratiﬁ ed by study site. To achieve 
treatment concealment, TMP-SMX and either placebo or 
doxycycline were dispensed into sequential, identical, 
tamper-proof bottles for each participant for 20 weeks. The 
study drug bottles were labelled with sequential code 
numbers and distributed to the study sites. TMP-SMX, 
placebo, and doxycycline were manufactured and provided 
by the Siam Pharmaceutical Company (Bangkok, Thailand). 
All patients and study investigators were unaware of the 
drug allocation throughout the study. The randomisation 
codes remained sealed until after data collection, data 
cleaning, and completion of a masked analysis.
Procedures
All patients received TMP-SMX plus placebo or TMP-
SMX plus doxycycline for a minimum of 20 weeks. TMP-
SMX (80 mg TMP and 400 mg SMX) tablets were 
prescribed using a weight-based dosage, as follows: 
bodyweight less than 40 kg or estimated glomerular 
ﬁ ltration rate 15–29 mL/min, 160 mg TMP and 800 mg 
SMX twice daily; bodyweight of 40 kg to 60 kg, 240 mg 
TMP and 1200 mg SMX twice daily; and bodyweight 
greater than 60 kg, 320 mg TMP and 1600 mg SMX twice 
daily.13 Doxycycline or placebo was prescribed as a 100 mg 
tablet to be taken twice daily. Patients were advised to 
repeat the dose if vomiting occurred within 30 min of 
their taking the tablet. The minimum duration of 
20 weeks was based on a combination of current practice 
and available evidence. The recommended duration for 
oral antimicrobials is 12–20 weeks in Thailand,6 and 
3–6 months in Australia,14 a discrepancy that shows the 
uncertainty about the optimum duration. Findings from 
a retrospective study in Thailand showed that treatment 
for longer than 12 weeks was associated with lower risk 
of relapse.6 We therefore chose to use 20 weeks as a 
minimum duration rather than 12 weeks or an 
empirically chosen point between the two.
After enrolment, we followed patients up at weeks 4, 
12, and 20 of oral treatment, every 4 months for 1 year after 
completion of treatment, and annually thereafter to the 
end of the study. Patients who did not attend scheduled 
appointments were contacted by telephone. The trial was 
designed to stop 1 year after the last participant was 
enrolled. At each clinical visit, we undertook a clinical 
examination and laboratory analyses, including complete 
blood count, blood sugar, blood urea nitrogen, creatinine, 
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electrolyte, and liver function tests. Chest radiography and 
abdominal ultrasonography were done at enrolment, and 
repeated at weeks 12 and 20 if an abnormality was detected 
on the ﬁ rst test. We asked patients to bring the study drug 
bottles to follow-up visits, at which drug compliance was 
checked by pill counts. Treatment with the randomised 
drugs was extended beyond 20 weeks if clinically indicated 
because of evidence of residual infection, as decided by 
the treating physician. Concealed study drug bottles 
labelled with unique spare sequential code numbers were 
separately prepared for patients who needed treatment for 
more than 20 weeks. As needed, the site investigator 
contacted the coordinating centre by telephone to receive 
the code number of the extended study drug bottles for a 
speciﬁ c study participant.
Study treatment was stopped immediately if a patient 
developed symptoms or signs of a severe allergic reaction 
(grade 4),15 and treatment was completed with the second-
line regimen (amoxicillin-clavulanic acid).6 Patients who 
were not able to tolerate the study drugs because of other 
adverse drug reactions and those who had an inadequate 
response to the study drugs as judged by the treating 
physician were also switched to amoxicillin-clavulanic 
acid. Amoxicillin-clavulanic acid was prescribed 
according to a weight-based dosage, as follows: 
bodyweight less than 60 kg: 1000 mg amoxicillin and 
250 mg clavulanic acid three times daily, and bodyweight 
greater than 60 kg: 1500 mg amoxicillin and 375 mg 
clavulanic acid three times daily.16
Outcomes and data management
The primary outcome of the study was culture-conﬁ rmed 
recurrent melioidosis, which was deﬁ ned as the 
development of new symptoms and signs of infection in 
association with at least one culture from any site positive 
for B pseudomallei at any time between enrolment and 
study completion. Secondary endpoints were overall 
recurrent melioidosis (culture-conﬁ rmed recurrent 
melioidosis plus clinical recurrence), mortality, treatment 
failure, extension of treatment, and adverse drug 
reactions. The published protocol contains an error and 
states that mortality was a primary rather than a 
secondary outcome measure (appendix). Clinical 
recurrence was deﬁ ned as the development of new 
symptoms and signs of infection that were consistent 
with melioidosis but in the absence of a positive 
B pseudomallei culture from any site. Treatment failure 
was deﬁ ned as the clinical decision to change oral 
treatment as a result of inadequate response. Extension 
of treatment was deﬁ ned as a decision by the treating 
physician to continue the study drug beyond 20 weeks. 
Adverse drug reactions were graded according to the 
National Cancer Institute Common Toxicity Criteria.15
Genotyping and deﬁ nition of relapse and re-infection
We compared B pseudomallei isolated on enrolment and at 
the recurrent episode using a combination of pulsed-ﬁ eld 
gel electrophoresis and multilocus sequence typing, as 
described previously.6,17 Relapse and re-infection were 
deﬁ ned on the basis of bacterial typing. Isolates from the 
same patient with an identical banding pattern on pulsed-
ﬁ eld gel electrophoresis were considered to be from the 
same strain and these patients were classiﬁ ed as having 
had a relapse. Isolates from the same patient that diﬀ ered 
by one or more bands were further examined with 
multilocus sequence typing.6,17 Isolates from the same 
patient with a diﬀ erent sequence type were classiﬁ ed as 
representing re-infection, whereas those with an identical 
sequence type were classiﬁ ed as being a relapse.
Statistical analysis
The trial was powered for non-inferiority at the completion 
of the study.18,19 We chose a non-inferiority design rather 
than a superiority design because the intervention group 
(TMP-SMX plus placebo) received fewer antimicrobials 
than the control group (TMP-SMX plus doxycycline), and 
we hypothesised that the intervention regimen was not 
superior to the standard regimen (TMP-SMX plus 
doxycycline), but had equivalent eﬃ  cacy. The expected 
incidence rate for the primary endpoint (culture-
conﬁ rmed recurrent melioidosis) was based on the results 
of the most recent, previous randomised controlled trial.7 
The non-inferiority margin was deﬁ ned by the scientiﬁ c 
committee as a hazard ratio for culture-conﬁ rmed 
recurrent melioidosis of 1·7. We calculated that 
600 participants were needed to determine non-inferiority 
with a power of 80% at an alpha error of 5%.
All patients were analysed on the basis of their original 
allocation group (intention-to-treat analysis). Continuous 
variables are presented as median (IQR). IQRs are 
presented in terms of 25th and 75th percentiles. 
Categorical data are presented as number (%). We did 
survival analyses using the Kaplan-Meier method and 
Cox proportional hazard models. Time was measured 
from the day of study enrolment. For the primary analysis 
(intention-to-treat analysis) with culture-conﬁ rmed 
recurrent melioidosis as the failure outcome, participants 
were censored on the day of last follow-up or death due to 
other causes. We tested non-inferiority of the TMP-SMX 
626 enrolled and randomly allocated
 to treatment
311 allocated to TMP-SMX plus placebo 
  for 20 weeks
315 allocated to TMP-SMX plus doxycycline 
  for 20 weeks
122 adverse drug reactions
 16 culture-confirmed recurrent infection
 10 clinical recurrent infection
 19 died
167 adverse drug reaction
 21 culture-confirmed recurrent infection
 8 clinical recurrent infection
 26 died
Figure 1: Trial proﬁ le
TMP-SMX=trimethoprim-sulfamethoxazole.
See Online for appendix
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plus placebo group by calculating the HR for the eﬃ  cacy 
of TMP-SMX plus placebo over the TMP-SMX plus 
doxycycline, and compared the upper limit of the 95% CI 
to the non-inferiority margin. To accept the non-
inferiority of TMP-SMX plus placebo to TMP-SMX plus 
doxycycline, the upper limit of the 95% CI needed to be 
equal to or less than 1·7. A one sided-test at an alpha error 
of 5% was also calculated for the non-inferiority margin. 
For the secondary analyses with treatment changes and 
treatment failure as the outcomes, participants were 
censored on the day of recurrent melioidosis or death 
due to other causes. We calculated the probabilities of 
event outcomes at each timepoint using the Kaplan-
Meier method. For the Cox Proportional Hazard model, 
we assessed whether the hazard ratio was constant over 
time using Schoenfeld residuals. The analysis was 
repeated for the primary outcome in the per-protocol 
population, in which those who did not complete 
20 weeks of study drug were excluded.
As recurrent melioidosis can be caused by either 
relapse or re-infection, we also assessed the eﬃ  cacy of 
TMP-SMX for culture-conﬁ rmed relapse in a sensitivity 
analysis on the basis that we would not expect 
antimicrobial treatment to prevent re-infection after 
treatment has been completed. We did this using culture-
conﬁ rmed relapse as a failure outcome and excluding 
patients who had no paired bacterial isolates available for 
genotyping from the ﬁ rst and recurrent episode and 
those with paired isolates and genotyping results that 
conﬁ rmed re-infection.
For safety analyses, we assessed the proportion of patients 
who had adverse drug reactions by treatment group. We 
compared proportions using the Fisher’s exact test and 
continuous variables using the Mann-Whitney test. We 
used STATA (version 12.1) for all statistical analyses.
Role of the funding source
The sponsors had no role in data collection, data analyses, 
data interpretation, or writing of the report. The 
corresponding author had full access to all the data in the 
study. All authors participated in the ﬁ nal discussion and 
approved the submission for publication.
Results
Between Oct 24, 2005, and Feb 1, 2010, we randomly 
assigned 626 patients with culture-conﬁ rmed melioidosis 
to receive either oral TMP-SMX plus placebo (n=311), or 
oral TMP-SMX plus doxycycline (n=315; ﬁ gure 1). 
Baseline characteristics were comparable between the 
two treatment groups (table 1). There were no missing 
data for baseline characteristics. Overall, 40 patients (6%) 
did not require parenteral antimicrobial treatment before 
enrolment, and 357 patients (57%) were deemed to need 
longer than 14 days of parenteral treatment before 
starting oral treatment. Most patients had a bodyweight 
between 40 kg and 60 kg and received 320 mg of TMP 
with 1600 mg of SMX twice daily (table 1).
TMP-SMX plus placebo 
group (n=311)
TMP-SMX plus doxycycline 
group (n=315)
Study site
Sappasithiprasong Hospital, Ubon Ratchathani 178 (57%) 184 (58%)
Srinagarind Hospital, Khon Kaen 47 (15%) 46 (15%)
Udon Thani Hospital, Udon Thani 39 (13%) 38 (12%)
Mahasarakam Hospital, Mahasarakam 24 (8%) 25 (8%)
Khon Kaen Hospital, Khon Kaen 23 (7%) 22 (7%)
Men 198 (64%) 193 (61%)
Age in years 51 (41–61) 50 (40–59)
Underlying diseases
Diabetes mellitus 196 (63%) 217 (69%)
Renal stones 19 (6%) 23 (7%)
Chronic kidney disease 17 (5%) 14 (4%)
Thalassaemia 12 (4%) 10 (3%)
Other diseases* 15 (5%) 17 (5%)
Distribution of melioidosis†
Localised 129 (41%) 134 (43%)
Multifocal 35 (11%) 51 (16%)
Bacteraemic 99 (32%) 89 (28%)
Disseminated 48 (15%) 41 (13%)
Organ involvement‡
Pneumonia 99 (32%) 109 (35%)
Skin or subcutaneous abscess 93 (30%) 100 (32%)
Splenic abscess 61 (20%) 56 (18%)
Liver abscess 46 (15%) 44 (14%)
Arthritis or osteomyelitis 24 (8%) 32 (10%)
Urinary tract infection 22 (7%) 22 (7%)
Lymphadenopathy 4 (1%) 9 (3%)
Other§ 12 (5%) 10 (4%)
Duration of parenteral antimicrobials before study drug
None 17 (5%) 23 (7%)
1–14 days 113 (36%) 116 (37%)
15–28 days 127 (41%) 129 (41%)
≥29 days 54 (17%) 47 (15%)
Estimated glomerular ﬁ ltration rate
≥60 mL/min per 1·73m² 188 (60%) 197 (63%)
30–59 mL/min per 1·73m² 99 (32%) 89 (28%)
15–29 mL/min per 1·73m² 24 (8%) 29 (9%)
Dosage of TMP-SMX received at enrolment
160/800 mg twice daily 25 (8%) 31 (10%)
240/1200 mg twice daily 250 (80%) 241 (76%)
320/1600 mg twice daily 36 (12%) 43 (14%)
Data are n (%) or median (IQR). TMP-SMX=trimethoprim-sulfamethoxazole. *Included steroid intake (12 patients), 
cirrhosis (eight patients), haemoglobinopathy (seven patients), chronic liver disease (six patients), cancer (six 
patients), and immunosuppressive drug intake (four patients). †Localised was deﬁ ned as a single focus of infection and 
a negative blood culture result, multifocal as more than one contiguous focus of infection and a negative blood culture 
result, bacteraemic as a positive blood culture result plus a single or no identiﬁ able focus of infection, and 
disseminated as a positive blood culture result plus more than one non-contiguous focus of infection. ‡Organ 
involvement was deﬁ ned as the presence of clinical features or clinical specimen taken from the organ that was culture 
 positive for Burkholderia pseudomallei. §Included parotid abscess (ﬁ ve patients), mycotic aneurysm (four patients), 
central nervous system infection (three patients), prostatic abscess (two patients), eye infection (two patients), 
pericarditis (two patients), pancreatic abscess (one patient), sinusitis (one patient), cervicitis (one patient), and 
tubo-ovarian abscess (one patient).
Table 1: Baseline characteristics
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Follow-up was completed in Feb 21, 2011, 1 year after we 
enrolled the last patient. 618 patients (99%) had at least one 
follow-up assessment. Median follow-up duration was 
17 months (IQR 13–28) in the TMP-SMX plus placebo 
group and 19 months (16–31) in the TMP-SMX plus 
doxycycline group (p=0·06). Total duration of follow-up was 
536 person-years in the TMP-SMX plus placebo group and 
583 person-years in the TMP-SMX plus doxycycline group.
We recorded no between-group diﬀ erence in our 
primary analysis for culture-conﬁ rmed recurrent 
melioidosis (p=0·64; table 2). Non-inferiority of TMP-
SMX plus placebo was shown because the upper bound 
of the 95% CI was below the pre-deﬁ ned non-inferiority 
margin (one-sided p=0·01; ﬁ gure 2). The probability of 
having culture-conﬁ rmed recurrent melioidosis within 
1 year of enrolment was 3% and within 3 years of 
enrolment was 10% (ﬁ gure 3). Of 37 culture-conﬁ rmed 
recurrent melioidosis cases, seven (19%) occurred during 
20 weeks of oral treatment, 17 (46%) occurred during the 
ﬁ rst year of follow-up, four (11%) occurred between year 1 
and year 2 of follow-up, and nine (24%) occurred after 
2 years.
Comparison of secondary endpoints in the two 
treatment groups is shown in table 2. The incidence of 
overall recurrent melioidosis and overall mortality was 
not diﬀ erent between the two treatment groups (table 2). 
Of 45 participants who died, 14 (31%) died during 
20 weeks of oral treatment, 15 (33%) died during the ﬁ rst 
year of follow-up, six (13%) died between year 1 and 
year 2 of follow-up, and ten (22%) died after 2 years. 
Cause of death was culture-conﬁ rmed recurrent 
melioidosis (seven patients), clinical recurrent 
melioidosis (four patients), unknown causes (11 patients), 
and other diseases (23 patients). No deaths were 
attributed to an adverse reaction to the study drugs.
Overall, 516 (82%) patients received oral treatment for at 
least 12 weeks (including amoxicillin-clavulanic acid if 
patients needed switching) and 445 (71%) patients received 
oral treatment for at least 20 weeks. 37 (12%) of 311 patients 
given TMP-SMX plus placebo and 59 (19%) of 315 patients 
given TMP-SMX plus doxycycline switched treatment to 
amoxicillin-clavulanic acid because of adverse drug 
reactions. Patients given TMP-SMX plus placebo had 
about a 40% lower chance of switching to the second-line 
regimen due to adverse drug reactions than those given 
TMP-SMX plus doxycycline (HR 0·61; 95% CI 0·41–0·92; 
p=0·02). Six patients (2%) given TMP-SMX plus placebo 
and six patients (2%) given TMP-SMX plus doxycycline 
switched due to treatment failure (HR 0·92; 0·30–2·87; 
p=0·89). Analysis of Schoenfeld residuals showed that the 
HR for all outcomes were not variable over time with the 
exception of switching due to treatment failure (Schoenfeld 
test, p=0·05). Of all patients who completed 20 weeks of 
the study drug, nine (4%) of 226 patients in the TMP-SMX 
plus placebo group and 12 (6%) of 218 patients in the TMP-
SMX plus doxycycline group needed an extension of 
treatment beyond 20 weeks (p=0·51).
The proportion of patients reporting adverse drug 
reactions was lower in the TMP-SMX plus placebo 
group than in the TMP-SMX plus doxycycline group 
(table 3). Common adverse drug reactions were allergic 
reactions and gastrointestinal disorders. Serious 
adverse events (grade 4) were reported in ﬁ ve patients 
(2%) given TMP-SMX plus placebo and eight patients 
(3%) given TMP-SMX plus doxycycline. These serious 
adverse events included Stevens-Johnson syndrome 
(three patients), severe hyponatraemia (<120 mmol/L; 
two patients), and severe hyperkalaemia (>7 mmol/L; 
one patient).
We analysed 226 patients in the TMP-SMX plus placebo 
group and 218 patients in the TMP-SMX plus doxycycline 
group who completed 20 weeks of the study drug in a per-
protocol analysis. Non-inferiority of TMP-SMX plus 
placebo for culture-conﬁ rmed recurrent melioidosis was 
also shown (HR 0·50, 95% CI 0·19–1·32).
We did bacterial genotyping for 29 (78%) of 37 patients 
with culture-conﬁ rmed recurrent melioidosis for whom 
paired isolates (from the primary and recurrent episode) 
were available. 14 recurrent cases (48%) were deﬁ ned as 
relapse, and 15 recurrent cases (52%) were deﬁ ned as re-
infection. Median time to relapse (7 months, IQR 6–13) 
TMP-SMX plus 
placebo group 
(n=311)
TMP-SMX plus 
doxycycline group 
(n=315)
Hazard ratio 
(95% CI; p value)
Recurrent melioidosis
Culture-conﬁ rmed 16 (5%) 21 (7%) 0·81 (0·42–1·55; p=0·64)
Clinical 10 (3%) 8 (3%) ··
Overall 26 (8%) 29 (9%) 0·95 (0·56–1·62; p=0·85)
Mortality
Due to recurrent melioidosis 8 (3%) 3 (1%) ··
Due to other causes 11 (4%) 23 (7%) ··
Overall 19 (6%) 26 (8%) 0·79 (0·44–1·43; p=0·44)
Discontinued study drug
Due to adverse event 37 (12%) 59 (19%) 0·61 (0·41–0·92; p=0·02)
Due to treatment failure 6 (2%) 6 (2%) 0·92 (0·30–2·87; p=0·89)
Extended study drug 9/226 (4%) 12/218 (6%) ··
Data are n (%) or n/N (%), unless otherwise stated. TMP-SMX=trimethoprim-sulfamethoxazole.
Table 2: Outcomes of the study
Hazard ratio
Culture-confirmed recurrent melioidosis
Overall recurrent melioidosis
Mortality 
1·000·250·10 3·001·70
1·55
1·62
1·43
0·50
Favours TMP-SMX 
plus doxycycline
Favours TMP-SMX
Figure 2: Non-inferiority of TMP-SMX relative to TMP-SMX plus doxycycline
Datapoints are the point estimate of the hazard ratio (HR) between the trimethoprim-sulfamethoxazole 
(TMP-SMX) plus placebo group and TMP-SMX plus doxycycline group. Error bars are 95% CI. Clinical equivalence of 
TMP-SMX would be accepted if the upper bound of the 95% CI of the HR for culture-conﬁ rmed recurrent 
melioidosis (primary endpoint) was below the pre-deﬁ ned non-inferiority margin (HR 1·7; dotted line).
Articles
812 www.thelancet.com   Vol 383   March 1, 2014
was shorter than median time to re-infection (29 months; 
13–37; p=0·0009).
In a sensitivity analysis (n=603), we excluded 15 patients 
who developed genotype conﬁ rmed re-infection and 
eight patients who did not have paired isolates for 
genotyping (appendix). These results did not diﬀ er 
substantially from the main analysis, although the 
95% CIs were wider as a consequence of the inclusion of 
fewer failure outcomes. Baseline characteristics were 
comparable between the two treatment groups 
(appendix). Of the 14 patients with culture-conﬁ rmed 
relapse, ﬁ ve were in the TMP-SMX plus placebo group 
(2% of 300 patients in this group included in the 
sensitivity analysis), and nine were in the TMP-SMX plus 
doxycycline group (3% of the 303 patients in the group; 
HR 0·58, 95% CI 0·19–1·73; p=0·33; appendix). The 
lower boundary of the 95% CI for the HR for culture-
conﬁ rmed relapse was slightly greater than the non-
inferiority margin (1·73 vs 1·70). In this analysis, 
14 patients (5%) given TMP-SMX plus placebo and 
24 patients (8%) given TMP-SMX plus doxycycline died 
during the study period (HR 0·61, 0·31–1·17; p=0·14; 
appendix). Patients given TMP-SMX plus placebo also 
had about a 40% lower chance of switching to the second-
line regimen due to adverse drug reactions than did 
those given TMP-SMX plus doxycycline (HR 0·56, 
0·3–0·85; p=0·01; appendix).
Discussion
Our ﬁ ndings suggest that TMP-SMX is not inferior to 
TMP-SMX plus doxycycline as an oral treatment for 
melioidosis. Fewer patients given TMP-SMX plus 
placebo had adverse drug reactions or switched to the 
second-line regimen compared with those given TMP-
SMX plus doxycycline. These ﬁ ndings provide the 
evidence for a change to the recommended oral regimen 
for melioidosis to TMP-SMX alone.
The probability of having culture-conﬁ rmed recurrent 
melioidosis within 1 year of enrolment into the study (3%) 
was lower than that seen in another trial (6%),7 in which 
the minimum duration of oral TMP-SMX and doxycycline 
was 12 weeks. Other factors that might explain the 
diﬀ erence in recurrence include better drug compliance in 
this study resulting from pill counting and phone contact 
to improve follow-up, which were not done in the other 
trial.7 In this study, 82% of participants received oral 
treatment for at least 12 weeks compared with only 69% in 
the previous trial.7 Moreover, fewer patients in the TMP-
SMX plus doxycycline group switched to the second-line 
drug regimen in this study compared with patients given 
the same treatment regimen in the previous trial (21% vs 
25%).7 Fewer switches to the second-line drug regimens by 
the treating clinicians in this study might be associated 
with the ﬁ nding of a retrospective study that showed  a 
doubling in risk of relapse (HR 2·1) associated with 
second-line regimens (including amoxicillin-clavulanic 
acid) compared with TMP-SMX-based regimens.6
TMP-SMX plus 
placebo group 
(n=311)
TMP-SMX plus 
doxycycline group 
(n=315)
Allergic reactions
Rash 25 (8%) 48 (15%)
Pruritus 8 (3%) 7 (2%)
Photosensitivity 0 22 (7%)
Stevens-Johnson syndrome 0 3 (1%)
Gastrointestinal disorders
Increased aspartate aminotransferase or alanine 
aminotransferase concentrations (>5 × ULN)
7 (2%) 9 (3%)
Nausea 20 (6%) 45 (14%)
Vomiting 21 (7%) 47 (15%)
Anorexia 3 (1%) 5 (2%)
Dyspepsia 5 (2%) 5 (2%)
Genitourinary disorder
Increased creatinine concentrations (≥ two times compared 
with baseline)
10 (3%) 9 (3%)
Haematological disorder
Anaemia (haemoglobin concentrations decreased ≥2 g/dL) 16 (5%) 20 (6%)
Thrombocytopenia (<50 000 per mm³) 3 (1%) 7 (2%)
Metabolic disorder
Hyponatraemia (<130 mmol/L) 28 (9%) 19 (6%)
Hyperkalaemia (>6 mmol/L) 13 (4%) 13 (4%)
Hypokalaemia (<3 mmol/L) 6 (2%) 3 (1%)
Musculoskeletal disorders
Myalgia 2 (1%) 5 (2%)
Neurological disorders
Dizziness 2 (1%) 2 (1%)
Other adverse drug reactions* 7 (2%) 13 (4%)
Overall 122 (39%) 167 (53%)
Data are n (%). TMP-SMX=trimethoprim-sulfamethoxazole. ULN=upper limit of normal. *Included nail change (three 
patients), peripheral oedema (three patients), generalised allergic reaction (two patients), headache (two patients), 
malaise (two patients), glossitis (two patients), alopecia (two patients), diarrhoea (one patient), insomnia (one patient), 
tinnitus (one patient), and hypoglycaemia (one patient).
 Table 3: Adverse drug reactions
Figure 3: Kaplan-Meier curves of probability without culture-conﬁ rmed recurrent melioidosis
TMP-SMX=trimethoprim-sulfamethoxazole.
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Findings from our bacterial genotyping analysis showed 
that half of recurrent infection was due to relapse, with 
the remainder being due to re-infection. This ﬁ nding 
contrasts with the ﬁ ndings of a retrospective study of 
921 patients with melioidosis over an 8 year period, in 
which 74% of recurrent infections (80 of 116) were due to 
relapse and 26% (30 of 116) were due to re-infection.6 One 
possible explanation is that in the retrospective study, 
50% of 921 patients were initially treated with non TMP-
SMX-based regimens which were associated with a 
higher rate of relapse. Use of genotyping to diﬀ erentiate 
between relapse and re-infection in melioidosis is well 
described.6,20 The chance of re-infection with 
B pseudomallei that belongs to the same genotype as that 
causing the primary infection is low because the genetic 
diversity of B pseudomallei strains in soil and water is 
high.21,22 Furthermore, the chance that relapse is caused 
by an isolate that belongs to a diﬀ erent genotype to that of 
the isolate cultured during the primary infection would 
require mixed infection with two or more bacterial 
strains, the incidence of which is very low.23 Our ﬁ ndings 
indicate that patients with melioidosis who are starting 
oral treatment should receive education about the 
prevention of melioidosis re-infection, including avoiding 
direct contact with soil or environmental water, avoiding 
outdoor exposure to heavy rain or dust clouds, and not 
drinking untreated water.24 Such strategies should be 
practical in Thailand: ﬁ ndings from our case-control 
study showed that a proportion of participants wore boots 
while farming and drank boiled water.24 Further studies 
are needed to assess the eﬀ ectiveness of preventive 
education given to populations at risk of re-infection, as 
well as those at risk for a ﬁ rst infective episode.
Although our study, to the best of our knowledge, is the 
largest randomised controlled trial to compare two drug 
regimens for the oral treatment of melioidosis and the 
ﬁ rst to use a non-inferiority design, it has several 
potential limitations. The ﬁ rst relates to the non-
inferiority margin (HR 1·7), which was selected by the 
scientiﬁ c committee on the basis of a balance between 
trial feasibility (completion within 4 years) and statistical 
robustness. Some investigators have suggested the 
adoption of a larger non-inferiority margin (HR 2·0), but 
we considered it unacceptable to adopt a new regimen 
that could actually have two times the risk of recurrent 
culture-conﬁ rmed melioidosis than the current standard. 
Some investigators have also suggested the adoption of a 
smaller non-inferiority margin (HR 1·5), but this would 
have required an 8 year study period with a sample size 
of 1200 patients, which we thought to be unfeasible. The 
scientiﬁ c committee agreed that an upper boundary of 
the 95% CI of a HR that was equal to or less than 
1·7 would be suﬃ  cient to change clinical practice to the 
use of TMP-SMX alone for oral treatment of melioidosis. 
Additional limitations were that 11 patients who died at 
home of unknown cause might have died from recurrent 
melioidosis, that eight (21%) of 37 paired B pseudomallei 
isolates were not available for genotyping, and that non-
inferiority was not shown in a sensitivity analysis. We 
also acknowledge that CLSI do not provide criteria for 
the interpretation of disc diﬀ usion and Etest assays for 
B pseudomallei,11 but these were used on the basis that 
they have been described previously,12,25 are in common 
use in Thailand, and were the only feasible option to 
establish susceptibility in the ﬁ ve study sites. The 
estimated HR of discontinuation of the study drug due to 
treatment failure (HR 0·92; table 2) should be interpreted 
with caution because the Schoenfeld test provided weak 
evidence suggesting that the HR for this outcome might 
not be constant over time.
In this study, we also assessed the eﬃ  cacy of TMP-
SMX over TMP-SMX plus doxycycline for culture-
conﬁ rmed relapse. The results from a sensitivity analysis 
were very similar to the main analysis, except that the 
lower bound of the 95% CI for the HR for culture-
conﬁ rmed relapse was slightly greater than the non-
inferiority margin. This ﬁ nding is mainly because the 
study was not powered to assess the non-inferiority based 
on this outcome in the sensitivity analysis. Therefore, we 
would suggest that these potential limitations are 
unlikely to have aﬀ ected the conclusions of the study.
Panel: Research in context
Systematic review
We searched PubMed for randomised controlled trials that assessed oral antimicrobial 
treatment for melioidosis published in English between Jan 1, 1921, and Dec 31, 2012, 
using the following MeSH terms (“melioidosis” OR “pseudomallei”) AND “trial”. We 
searched bibliographies from selected studies for secondary references. We identiﬁ ed four 
randomised controlled trials (Rajchanuvong and colleagues,26 Chaowagul and colleagues,27 
Chetchotisakd and colleagues,28 and Chaowagul and colleagues7). All four trials used 
culture-conﬁ rmed recurrent melioidosis as the primary outcome. The trial done by 
Rajchanuvong et al26 compared amoxicillin-clavulanic acid with a combination of 
TMP-SMX, doxycycline, and chloramphenicol. Their ﬁ ndings suggested that amoxicillin-
clavulanic acid was less eﬀ ective, and they recommended that amoxicillin-clavulanic acid 
should be used as a second-line regimen. Chaowagul and colleagues27 compared 
doxycycline alone with a combination of TMP-SMX, doxycycline, and chloramphenicol, 
and showed that doxycycline alone was not eﬀ ective for the treatment of melioidosis. 
Chetchotisakd and colleagues28 compared oral ciproﬂ oxacin plus azithromycin with TMP-
SMX plus doxycycline and showed that ciproﬂ oxacin plus azithromycin was not eﬀ ective 
for the treatment of melioidosis. The trial published by Chaowagul and colleagues27 in 
2005 compared TMP-SMX plus doxycycline with a combination of TMP-SMX, doxycycline, 
and chloramphenicol. TMP-SMX plus doxycycline was not diﬀ erent from a combination 
of TMP-SMX, doxycycline, and chloramphenicol, and TMP-SMX plus doxycycline was 
recommended as the standard for oral treatment on the basis of fewer side-eﬀ ects.
Interpretation
To our knowledge, our trial is the ﬁ rst to compare TMP-SMX alone with TMP-SMX plus 
doxycycline as oral antimicrobial treatment for melioidosis, and the ﬁ rst melioidosis trial 
to use a non-inferiority design. Both regimens (TMP-SMX alone and TMP-SMX plus 
doxycycline) are used in clinical practice. Our trial shows that TMP-SMX alone is not inferior 
to TMP-SMX plus doxycycline, and we propose that TMP-SMX alone should be used on the 
basis of safety and patient tolerance.
Articles
814 www.thelancet.com   Vol 383   March 1, 2014
Having established that TMP-SMX is preferable to 
TMP-SMX and doxycycline for the oral phase of 
melioidosis treatment (panel), the next challenge is to 
establish the optimum duration of this regimen.
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